CN102106856B - Entecavir medicinal composition and preparation method thereof - Google Patents
Entecavir medicinal composition and preparation method thereof Download PDFInfo
- Publication number
- CN102106856B CN102106856B CN 201010222223 CN201010222223A CN102106856B CN 102106856 B CN102106856 B CN 102106856B CN 201010222223 CN201010222223 CN 201010222223 CN 201010222223 A CN201010222223 A CN 201010222223A CN 102106856 B CN102106856 B CN 102106856B
- Authority
- CN
- China
- Prior art keywords
- pellet core
- entecavir
- fine pellet
- dissolved
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a medicinal composition of Entecavir, in particular to a medicinal composition, which is suitable for oral administration, of Entecavir and a preparation method thereof. The Entecavir medicinal composition comprises Entecavir, a bonding agent, a plasticizer and a medicinal carrier substrate, wherein the Entecavir is adhered to the medicinal carrier substrate.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition of Entecavir, relate in particular to a kind of pharmaceutical composition that is fit to oral Entecavir and preparation method thereof.
Background technology
Entecavir (Entecavir) is a kind of oral antiviral medicament, developed by Bristol-Myers Squibb Co. (Bristol-Myers Squibb) at first, in February, 2006, entecavir tablets was got permission listing in China, its chemistry [1S-(1 α, 3 α, 4 β)]-2-amino-1 by name, 9-dihydro-9-[4-hydroxyl-3-(methylol)-2-methylene cyclopenta]-the 6H-purine-6-one, slightly soluble in water, dissolubility is 2.4mg/mL, has following structural formula:
The peroral dosage form of Entecavir has capsule, tablet, drop pill etc.Chinese patent application CN101028271, CN101371841, CN101703489, CN1883459 disclose the entecavir capsule agent, and CN1732944, CN101069687, CN101244044 disclose the dispersible tablet of Entecavir.Content due to Entecavir in single dose is smaller, is only 0.5mg or 1mg, makes the content of effective ingredient be difficult to keep constant between each single dose.
Therefore, provide the entecavir medicinal composition that a kind of content is even, batch difference is minimum, steady quality also is fit to suitability for industrialized production to have larger meaning.Wherein batch difference not only comprises the difference between different batches, also comprises the difference between single dose in same batch.
Summary of the invention
The object of the present invention is to provide a kind of uniformity of dosage units high, batch difference is minimum, stay-in-grade Entecavir drug oral compositions.
Entecavir medicinal composition provided by the invention comprises Entecavir, binding agent, plasticizer and pharmaceutically suitable carrier substrate, and wherein Entecavir is adhered on pharmaceutically suitable carrier substrate, and content is for being 0.1%～2%, preferred 0.2%～1% of compositions gross weight.
The binding agent that is fit to comprises polyvidone, methylcellulose, hydroxypropyl cellulose, hydroxy methocel, hypromellose, hydroxyethyl-cellulose, starch slurry, dextrin, Icing Sugar, syrup, rubber cement, sodium carboxymethyl cellulose, sodium alginate, Polyethylene Glycol, Magnesiumaluminumsilicate, preferred hypromellose.In compositions, the content of binding agent is preferably approximately 3%～20% of compositions gross weight, is preferably 8%～15%.
The plasticizer that is fit to comprises Polyethylene Glycol, propylene glycol, glycerol, triacetin, Oleum Ricini, acetylation monoglyceride, phthalic acid ester, silicone oil, span, polyoxyethylene sorbitan carboxylic ester, polysorbate80; preferred propylene glycol, glycerol, Polyethylene Glycol, most preferably Polyethylene Glycol.In compositions, the content of plasticizer is preferably approximately 0.05%～1.5% of compositions gross weight, is preferably approximately 0.15～1.0%.
The pharmaceutically acceptable material that pharmaceutically useful carrier matrix refers to be easy to by coating and is difficult for assembling comprises microcrystalline Cellulose, calcium phosphate, dextrin, glucose, mannitol, sorbitol, sucrose, starch etc., and sucrose is preferred.Described carrier matrix can be celphere or fine pellet core, should be noted that, here micropill refers to that diameter is less than all kinds of ball of 2.Smm or the ball entity of class, celphere refers to not contain the prefabricated profiled microspheroidal ball of medicine active component, be a kind of intermediate pharmaceutic adjuvant, outward appearance is very round usually.In compositions, the content of carrier matrix is preferably approximately 65%～95% of compositions gross weight, is preferably 75%～90%.
Further, can also there be sealing coat between carrier matrix and Entecavir medicine layer, with contacting of buffering Entecavir medicine layer and carrier matrix, can also has sealing coat in the outside of medicine layer.The composition of sealing coat is generally the water-soluble material that is easy to film forming, as cellulose derivative (as hypromellose, hydroxypropyl cellulose, methylcellulose, ethyl cellulose, hydroxyethyl-cellulose), polyvidone, acrylic resin etc.
Further preferred, in sealing coat and Entecavir medicine layer, add antiplastering aid, thereby make the gathering of granule drop to minimum.Wherein antiplastering aid is preferably Pulvis Talci.
The invention still further relates to the suitable oral pharmaceutical composition that contains the low dosage Entecavir, wherein the content of Entecavir is 0.1～1mg.Said composition obtains by the surface that makes pharmaceutically active substance be adhered to carrier matrix.
Here be fit to oral pharmaceutical composition and comprise the forms such as tablet, capsule, granule or powder, be preferably tablet, capsule, most preferably be capsule.This class preparation also can comprise other pharmaceutically acceptable excipient, as filler, lubricant, disintegrating agent etc.
In one embodiment, entecavir medicinal composition of the present invention is entecavir capsule.
On the other hand, the present invention also provides a kind of method for preparing aforementioned pharmaceutical compositions, comprising:
(1) Entecavir, binding agent, plasticizer are dissolved in suitable quantity of water;
(2) solution with step (1) is sprayed onto on carrier matrix;
(3) carrier matrix of the described Entecavir coating of drying steps (2) is with desolventizing water;
(4) carrier matrix of the Entecavir coating of the drying of step (3) is made described pharmaceutical composition.
The drying of step (2) and step (3) can be completed in an equipment, as fluidized bed dryer, spray dryer.
Above-mentioned preparation method especially be fit to the preparation low dosage (be the pharmaceutical composition of 0.1～1mg) Entecavir as content, in step (3) carrier matrix of dry Entecavir coating can directly be filled in capsule or with disintegrating agent and/or mix lubricant after tabletting obtain tablet.
The filler that is fit to comprises starch, pregelatinized Starch, dextrin, sugar, lactose, mannitol, microcrystalline Cellulose etc.
The lubricant that is fit to comprises magnesium stearate, stearic acid, Pulvis Talci, hydrogenated vegetable oil, Polyethylene Glycol, Stepanol MG, sodium lauryl sulphate, stearyl fumarate and sodium lauryl sulfate, preferred magnesium stearate, sodium lauryl sulphate.
The disintegrating agent that is fit to comprises polyvinylpolypyrrolidone, cross-linked carboxymethyl cellulose, LH-21, carboxymethyl starch sodium, Explotab, pre-gelatinized starch and corn starch etc.
Entecavir of the present invention can be the Entecavir anhydride, can be also the Entecavir hydrate, as monohydrate.Relate to quality than the time all in anhydride.
The tablet of gained or capsule can be the film coatings, so that take.The suitable material that is used for the film coating is the coating materials of polymerization, pigment, plasticizer etc.The coating materials that is fit to comprises that hydroxypropyl methylcellulose, hydroxyethyl-cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose make phthalic acid ester etc.Suitable pigment comprises titanium dioxide and ferrum oxide.
Composition in coated composition is dispersed in suitable solvent, in preferred water.Coated composition can adopt conventional pan coating or spray coating technology to be used for tablet or capsule.
Entecavir medicinal composition of the present invention compared with prior art, advantage is: the prescription that (1) is selected to be fit to guarantees that Entecavir can be adhered on carrier matrix uniformly, special emphasis guarantees Entecavir adhering to minimum granularity on carrier matrix in Formulation, and be difficult for assembling, improved the uniformity that medicine disperses; (2) reduced the consumption of adjuvant in pharmaceutical composition as far as possible, avoided eating unnecessary pharmaceutic adjuvant in patient's long-term taking process and the unnecessary injury that causes; (3) the pharmaceutical composition reliable in quality that contains the Entecavir of above-mentioned adjuvant is stablized, and has guaranteed the safety of medication.
The specific embodiment
The below is described in further detail the present invention with specific embodiment, but content of the present invention is not limited to these embodiment.
Embodiment 1
Preparation 0.5mg entecavir capsule, concrete composition and content are as follows:
Entecavir 0.5g
Fine pellet core (sucrose) 100g
Hypromellose 15g
Polyethylene glycol 6000 0.24g
Pulvis Talci 8g
The capsule of 1000 Entecavirs of preparation, preparation method is as follows:
1) the 2g hypromellose is dissolved in suitable quantity of water, adds a small amount of Pulvis Talci, stir evenly standby;
2) recipe quantity polyethylene glycol 6000, Entecavir are dissolved in suitable quantity of water, add the 10g hypromellose, molten clear, then add appropriate Pulvis Talci, stir rear standby;
3) the 3g hypromellose is dissolved in suitable quantity of water, adds a small amount of Pulvis Talci, stir evenly standby;
4) the recipe quantity fine pellet core is placed in fluid bed, conditioning equipment sprays into 1 to appropriate state) solution prepared, give the fine pellet core bottoming;
5) continue to spray into 2) solution prepared, add medicine to fine pellet core;
6) continue again to spray into 3) solution prepared, to contagion gown on fine pellet core.Fluid bed inner drying after contagion gown on fine pellet core is in the gelatine capsule shell of packing into and get final product.
Embodiment 2
Preparation 0.5mg entecavir capsule, concrete composition and content are as follows:
Entecavir 0.5g
Fine pellet core (sucrose) 100g
Hypromellose 8g
Hydroxypropyl cellulose 4g
Polyethylene glycol 6000 0.14g
Pulvis Talci 8g
The capsule of 1000 Entecavirs of preparation, preparation method is as follows:
1) the 2g hydroxypropyl cellulose is dissolved in suitable quantity of water, adds a small amount of Pulvis Talci, stir evenly standby;
2) recipe quantity polyethylene glycol 6000, Entecavir are dissolved in suitable quantity of water, add the hypromellose of recipe quantity, molten clear, then add appropriate Pulvis Talci, stir rear standby;
3) the 2g hydroxypropyl cellulose is dissolved in suitable quantity of water, adds a small amount of Pulvis Talci, stir evenly standby;
4) the recipe quantity fine pellet core is placed in fluid bed, conditioning equipment sprays into 1 to appropriate state) solution prepared, give the fine pellet core bottoming;
5) continue to spray into 2) solution prepared, add medicine to fine pellet core;
6) continue again to spray into 3) solution prepared, to contagion gown on fine pellet core.Fluid bed inner drying after contagion gown on fine pellet core is in the gelatine capsule shell of packing into and get final product.
Embodiment 3
Preparation 1.0mg entecavir capsule, concrete composition and content are as follows:
Entecavir 1.0g
Fine pellet core (sucrose) 250g
Hypromellose 40g
Hydroxypropyl cellulose 10g
Polyethylene glycol 6000 0.94g
Pulvis Talci 25g
The capsule of 1000 Entecavirs of preparation, preparation method is as follows:
1) the 4g hydroxypropyl cellulose is dissolved in suitable quantity of water, adds a small amount of Pulvis Talci, stir evenly standby;
2) recipe quantity polyethylene glycol 6000, Entecavir are dissolved in suitable quantity of water, add the recipe quantity hypromellose, molten clear, then add appropriate Pulvis Talci, stir rear standby;
3) the 6g hydroxypropyl cellulose is dissolved in suitable quantity of water, adds a small amount of Pulvis Talci, stir evenly standby;
4) the recipe quantity fine pellet core is placed in fluid bed, conditioning equipment sprays into 1 to appropriate state) solution prepared, give the fine pellet core bottoming;
5) continue to spray into 2) solution prepared, add medicine to fine pellet core;
6) continue again to spray into 3) solution prepared, to contagion gown on fine pellet core.Fluid bed inner drying after contagion gown on fine pellet core is in the gelatine capsule shell of packing into and get final product.
Embodiment 4
Get 1 of entecavir capsule, remove capsule shells, put in the measuring bottle of 20ml, add the approximately 10ml dissolving of 0.01mol/L hydrochloric acid solution, continue to be diluted to scale, filter, get subsequent filtrate as need testing solution, press high effective liquid chromatography for measuring, chromatographic condition is as follows: octadecylsilane chemically bonded silica is filler; With acetonitrile-water (8: 92) mobile phase, flow velocity 1.0ml/min detects wavelength 254nm.Get at random respectively 10 capsules in embodiment 1-3, according to " two appendix XE of Chinese Pharmacopoeia 2005 version calculate, and result is as follows:
Table 1 entecavir capsule sample size uniformity data
| Numbering | Embodiment 1 | Embodiment 2 | Embodiment 3 |
| 1 | 102.8 | 99.7 | 98.1 |
| 2 | 99.6 | 98.0 | 99.7 |
| 3 | 98.1 | 98.3 | 100.4 |
| 4 | 99.3 | 103.1 | 101.4 |
| 5 | 98.2 | 99.5 | 98.8 |
| 6 | 98.9 | 97.0 | 100.1 |
| 7 | 99.1 | 101.5 | 103.0 |
| 8 | 98.4 | 99.7 | 100.1 |
| 9 | 99.5 | 101.1 | 97.6 |
| 10 | 101.4 | 99.6 | 95.0 |
| Meansigma methods | 99.5 | 99.7 | 99.4 |
| SD | 1.48 | 1.80 | 2.20 |
| A+1.8S | 3.14 | 3.49 | 4.53 |
As can be seen from Table 1, according to the capsule that preparation method of the present invention prepares, in every capsules, the content of Entecavir is very even.
Embodiment 5
The entecavir capsule of embodiment 1 is removed outer packing device in uncovered culture dish, be placed in 40 ℃ of calorstats, detect respectively at sampling in 5 days, 10 days.Testing result sees Table 2.
Table 2 hot test (40 ℃)
Embodiment 6
The entecavir capsule of embodiment 2 is removed outer packing device in uncovered culture dish, be placed in 60 ℃ of calorstats, detect respectively at sampling in 5 days, 10 days.Testing result sees Table 3.
Table 3 hot test (60 ℃)
Embodiment 7
The entecavir capsule of embodiment 3 is removed outer package, be placed in 25 ℃, in the vessel of RH75% sealing, carry out investigating in 5,10 days.Testing result sees Table 5.
The high wet test of table 4 (25 ℃, RH75%)
Influence factor's result of the test of embodiment 5-7 shows, under each condition, the sample indices, do not have significant change, illustrates that pharmaceutical composition quality stability of the present invention is good.
Claims (3)
1. 0.5mg entecavir capsule is comprised of following compositions:
Be prepared into the capsule of 1000 Entecavirs, described fine pellet core is sucrose, it is characterized in that preparation method is as follows:
1) the 2g hypromellose is dissolved in suitable quantity of water, adds a small amount of Pulvis Talci, stir evenly standby;
2) recipe quantity polyethylene glycol 6000, Entecavir are dissolved in suitable quantity of water, add the 10g hypromellose, molten clear, then add appropriate Pulvis Talci, stir rear standby;
3) the 3g hypromellose is dissolved in suitable quantity of water, adds a small amount of Pulvis Talci, stir evenly standby;
4) the recipe quantity fine pellet core is placed in fluid bed, conditioning equipment sprays into 1 to appropriate state) solution prepared, give the fine pellet core bottoming;
5) continue to spray into 2) solution prepared, add medicine to fine pellet core;
6) continue again to spray into 3) solution prepared, to contagion gown on fine pellet core, fluid bed inner drying after contagion gown on fine pellet core is in the gelatine capsule shell of packing into and get final product.
2. 0.5mg entecavir capsule is comprised of following compositions:
Be prepared into the capsule of 1000 Entecavirs, described fine pellet core is sucrose, it is characterized in that preparation method is as follows:
1) the 2g hydroxypropyl cellulose is dissolved in suitable quantity of water, adds a small amount of Pulvis Talci, stir evenly standby;
2) recipe quantity polyethylene glycol 6000, Entecavir are dissolved in suitable quantity of water, add the hypromellose of recipe quantity, molten clear, then add appropriate Pulvis Talci, stir rear standby;
3) the 2g hydroxypropyl cellulose is dissolved in suitable quantity of water, adds a small amount of Pulvis Talci, stir evenly standby;
4) the recipe quantity fine pellet core is placed in fluid bed, conditioning equipment sprays into 1 to appropriate state) solution prepared, give the fine pellet core bottoming;
5) continue to spray into 2) solution prepared, add medicine to fine pellet core;
6) continue again to spray into 3) solution prepared, to contagion gown on fine pellet core, fluid bed inner drying after contagion gown on fine pellet core is in the gelatine capsule shell of packing into and get final product.
3. 1.0mg entecavir capsule is comprised of following compositions:
Be prepared into the capsule of 1000 Entecavirs, described fine pellet core is sucrose, it is characterized in that preparation method is as follows:
1) the 4g hydroxypropyl cellulose is dissolved in suitable quantity of water, adds a small amount of Pulvis Talci, stir evenly standby;
2) recipe quantity polyethylene glycol 6000, Entecavir are dissolved in suitable quantity of water, add the recipe quantity hypromellose, molten clear, then add appropriate Pulvis Talci, stir rear standby;
3) the 6g hydroxypropyl cellulose is dissolved in suitable quantity of water, adds a small amount of Pulvis Talci, stir evenly standby;
4) the recipe quantity fine pellet core is placed in fluid bed, conditioning equipment sprays into 1 to appropriate state) solution prepared, give the fine pellet core bottoming;
5) continue to spray into 2) solution prepared, add medicine to fine pellet core;
6) continue again to spray into 3) solution prepared, to contagion gown on fine pellet core, fluid bed inner drying after contagion gown on fine pellet core is in the gelatine capsule shell of packing into and get final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010222223 CN102106856B (en) | 2010-06-29 | 2010-06-29 | Entecavir medicinal composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010222223 CN102106856B (en) | 2010-06-29 | 2010-06-29 | Entecavir medicinal composition and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102106856A CN102106856A (en) | 2011-06-29 |
| CN102106856B true CN102106856B (en) | 2013-06-19 |
Family
ID=44171212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010222223 Active CN102106856B (en) | 2010-06-29 | 2010-06-29 | Entecavir medicinal composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102106856B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102416003A (en) * | 2011-12-08 | 2012-04-18 | 南京优科生物医药有限公司 | Method for preparing entecavir tablets |
| CN102560036A (en) * | 2012-01-17 | 2012-07-11 | 杭州百木表面技术有限公司 | Copper strip annealing anti-sticking agent |
| CN103908436B (en) * | 2012-12-29 | 2016-02-10 | 安徽贝克生物制药有限公司 | A kind of quick-releasing type entecavir composite |
| CN103432098B (en) * | 2013-08-28 | 2014-12-10 | 南京正大天晴制药有限公司 | Entecavir capsule and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101028270A (en) * | 2007-02-02 | 2007-09-05 | 广东东阳光药业有限公司 | Enticawer release-controllable tablet and its preparation |
| CN101028271A (en) * | 2007-02-02 | 2007-09-05 | 广东东阳光药业有限公司 | Enticawer release-controllable capsules and their preparation |
-
2010
- 2010-06-29 CN CN 201010222223 patent/CN102106856B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101028270A (en) * | 2007-02-02 | 2007-09-05 | 广东东阳光药业有限公司 | Enticawer release-controllable tablet and its preparation |
| CN101028271A (en) * | 2007-02-02 | 2007-09-05 | 广东东阳光药业有限公司 | Enticawer release-controllable capsules and their preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102106856A (en) | 2011-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101190179B (en) | Enteric medicinal composition for treating diabetes and preparation method thereof | |
| CN101516356A (en) | Metoprolol succinate e.r. tablets and methods for their preparation | |
| CN101507718B (en) | Sodium rabeprazole enteric-coated orally disintegrating tablets and preparation method thereof | |
| MX2015002582A (en) | Pharmaceutical or nutraceutical composition with sustained release characteristic and with resistance against the influence of ethanol. | |
| CN104922086A (en) | Preparation method of proton pump inhibitor enteric-coated tablet | |
| CN102106856B (en) | Entecavir medicinal composition and preparation method thereof | |
| CN102579367A (en) | Topiramate sustained-release drug composition, method for preparing same and application of Topiramate sustained-release drug composition | |
| CN105456270A (en) | Dipeptidyl peptidase IV inhibitor pharmaceutical composition, use and preparation method thereof | |
| CN101428005A (en) | Pantoprazole and its sodium salt enteric sustained-release pellet preparation | |
| CN101322695A (en) | Piclofenac potassium sustained release capsule and preparing technique thereof | |
| CN102579408B (en) | Doxycycline hydrochloride dual-release preparation and preparation method thereof | |
| CN101129384B (en) | Method for preparing carbamazepine sustained-release capsules | |
| CN102058544B (en) | Method for preparing enteric slow release pellet containing fenofibric acid choline salt | |
| CN102762198A (en) | Multi-unit compositions | |
| CN100367967C (en) | Fasudic hydrochloride oral formulation | |
| CN105343028A (en) | Medicine composition with norfloxacin and method for preparing medicine composition | |
| CN102100677B (en) | Entecavir dispersible tablets and preparation method thereof | |
| CN105434398B (en) | A kind of Rabeprazole enteric-coated micro-pill and preparation method thereof | |
| CN101991720A (en) | Jiechangning target-oriented drug delivery preparation and application thereof | |
| CN105816441A (en) | Memantine hydrochloride and donepezil hydrochloride composite preparation | |
| CN103768071B (en) | A kind of oral formulations treating diabetes | |
| CN102138906B (en) | Clonidine hydrochloride sustained release micropill preparation | |
| KR100857061B1 (en) | Tablet containing vaccinium myrtillus extract and preparing method thereof | |
| CN104721148A (en) | Enteric-coated slow release pellet or particle solid preparation and production method thereof | |
| CN107530290A (en) | Slow release medical composition containing rivastigmine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: JIANGSU ZHENGDA TIANQING PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Address before: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee before: Jiangsu Chiatai Tianqing Pharmaceutical Co., Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. Effective date: 20131127 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 222006 LIANYUNGANG, JIANGSU PROVINCE TO: 210038 NANJING, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20131127 Address after: 210038 Jiangsu city of Nanjing Province Economic and Technological Development Zone No. 9 Ou Lu Hui Patentee after: Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Address before: 222006 Sinpo City, Lianyungang Province, North Road, No. 8, No. Patentee before: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |